title: Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment.
abstract: The maraviroc clinical test (MCT) is a clinical approach to establish the indication of maraviroc treatment. In this study, we analysed the long-term outcome of patients receiving a combined antiretroviral therapy (cART) selected according to MCT results. Ninety-two consecutive HIV-infected patients underwent MCT. A virological response (<40 HIV-RNA copies/ml after 24 weeks) was observed in 76/92 patients (82.6%). These patients (n=76) were included in a time to treatment failure analysis; after a mean follow-up period of 88 weeks, treatment failure was confirmed in 14 patients (18.4%). Tropism switch during MCT was observed in 3/35 patients (8.6%); these patients experienced excellent long-term outcome on cART. In conclusion, MCT should be considered as an additional method before CCR5-antagonists prescription.
authors: Laboratory of Immunovirology, Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, Seville 41013, Spain.
authors: Miguel
authors: M
authors: Genebat
authors: Ildefonso
authors: I
authors: Pulido
authors: M Concepción
authors: MC
authors: Romero-Sánchez
authors: Alejandro
authors: A
authors: González-Serna
authors: Sara
authors: S
authors: Ferrando-Martínez
authors: Kawthar
authors: K
authors: Machmach
authors: Yolanda M
authors: YM
authors: Pacheco
authors: M Ángeles
authors: MÁ
authors: Muñoz-Fernández
authors: Ezequiel
authors: E
authors: Ruiz-Mateos
authors: Manuel
authors: M
authors: Leal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D002648:Child; D003510:Cyclohexanes / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*; D019562:Viral Load; D056189:Viral Tropism; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc